Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression
OncologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Publicado em
- 29 fev 2024
- Citações
- 197
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression
Aditya Bardia, Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Kevin M. Kalinsky, Javier Cortés, Joyce O'Shaughnessy et al.
Descritores MeSH
- Cell Adhesion Molecules
- Erb-b2 Receptor Tyrosine Kinases
- Antigens, Neoplasm
- Antibodies, Monoclonal, Humanized
- Triple Negative Breast Neoplasms
- Humans
- Progression-Free Survival
- Neoplasm Metastasis
- Immunoconjugates
- Middle Aged